Magic mushroom therapy targets Cancer-Related depression

NCT ID NCT06200155

Recruiting now Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along with talk therapy. The study focuses on safety and how well the approach works for mental health symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could offer a new way to ease depression and anxiety in people with advanced cancer, improving their quality of life.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Psilocybin can cause temporary psychological distress, and the study focuses on safety and feasibility, not yet on effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder cancer Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER DEPRESSION, ANXIETY PSILOCYBIN-ASSISTED PSYCHOTHERAPY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.